Sevindik, O. Et Al. 2015. HYPOALBUMINEMIA IS A SURROGATE BIOMARKER OF POOR PROGNOSIS IN MYELODYSPLASTIC SYNDROME EVEN WHEN ADJUSTED WITH COMORBIDITIES. 13th International Symposium on Myelodysplastic Syndromes (MDS) , (Washington, Kiribati).

Sevindik, O., Guc, Z., KAHRAMAN, S., Medeni, S., Katgi, A., Acar, C., ... ALACACIOĞLU, İ.(2015). HYPOALBUMINEMIA IS A SURROGATE BIOMARKER OF POOR PROGNOSIS IN MYELODYSPLASTIC SYNDROME EVEN WHEN ADJUSTED WITH COMORBIDITIES . 13th International Symposium on Myelodysplastic Syndromes (MDS), Washington, Kiribati

Sevindik, O. Et Al. "HYPOALBUMINEMIA IS A SURROGATE BIOMARKER OF POOR PROGNOSIS IN MYELODYSPLASTIC SYNDROME EVEN WHEN ADJUSTED WITH COMORBIDITIES," 13th International Symposium on Myelodysplastic Syndromes (MDS), Washington, Kiribati, 2015

Sevindik, O. Et Al. "HYPOALBUMINEMIA IS A SURROGATE BIOMARKER OF POOR PROGNOSIS IN MYELODYSPLASTIC SYNDROME EVEN WHEN ADJUSTED WITH COMORBIDITIES." 13th International Symposium on Myelodysplastic Syndromes (MDS) , Washington, Kiribati, 2015

Sevindik, O. Et Al. (2015) . "HYPOALBUMINEMIA IS A SURROGATE BIOMARKER OF POOR PROGNOSIS IN MYELODYSPLASTIC SYNDROME EVEN WHEN ADJUSTED WITH COMORBIDITIES." 13th International Symposium on Myelodysplastic Syndromes (MDS) , Washington, Kiribati.

@conferencepaper{conferencepaper, author={O. Sevindik Et Al. }, title={HYPOALBUMINEMIA IS A SURROGATE BIOMARKER OF POOR PROGNOSIS IN MYELODYSPLASTIC SYNDROME EVEN WHEN ADJUSTED WITH COMORBIDITIES}, congress name={13th International Symposium on Myelodysplastic Syndromes (MDS)}, city={Washington}, country={Kiribati}, year={2015}}